不同年龄患者的原发性转移性乳腺癌（dnMBC）的预后结果以转移模式为特定尚不明确。本研究利用大规模数据调查了不同年龄dnMBC的转移模式与预后特征。将Surveillance、Epidemiology and End Results数据库（2010-2018）的24,698名dnMBC女性患者按年龄分成三组。使用χ²检验比较转移模式，并进行逻辑回归以研究年龄及特定器官转移风险。采用Kaplan-Meier生存曲线比较总生存率。 在三个组中，年轻组肝转移比例最大（35.2% vs. 28.2% vs. 21.1%，p < 0.001），老年组肺转移比例最大（22.6% vs. 30.0% vs. 35.0%，p < 0.001），骨转移比例最低（65.7% vs. 67.6% vs. 64.4%，p < 0.001）。在年轻组中，患有肝转移的患者预后较患有肺转移的患者更好（MST: 34个月 vs. 29个月，p = 0.041），而在中年和老年组中，肺转移的预后优于肝转移的预后（中年组MST：24个月vs. 20个月，p = 0.002；老年组MST：12个月vs. 6个月，p < 0.001）。 不同年龄dnMBC患者具有独特的转移模式和预后特征。研究结果支持针对不同年龄患者采用个体化管理和监测策略的考虑。 © 2023 The Authors. Cancer Medicine由John Wiley & Sons Ltd出版。

The prognostic outcomes of metastasis patterns in patients with de novo metastatic breast cancer (dnMBC) of different ages are unknown. Our study used a large-scale data to investigate the metastasis patterns and prognostic features in dnMBC of different ages.Total 24,698 women with dnMBC in the Surveillance, Epidemiology and End Results database (2010-2018) were divided into three groups by age. Chi-squared test was used to compare metastasis patterns and logistic regression was performed to investigate the risk of age and specific organ metastases. Kaplan-Meier survival curves were used to compare the overall survival.In three groups, young group had the largest proportion of liver metastases (35.2% vs. 28.2% vs. 21.1%, p < 0.001), and elderly group had the largest proportion of lung metastases (22.6% vs. 30.0% vs. 35.0%, p < 0.001) and the lowest proportion of bone metastases (65.7% vs. 67.6% vs. 64.4%, p < 0.001). In young group, patients with liver metastases had better prognosis than patients with lung metastases (MST: 34 months vs. 29 months, p = 0.041), but in middle-aged and elderly groups, the prognosis of lung metastases was better than that of liver metastases (MST in middle-aged group: 24 months vs. 20 months, p = 0.002; MST in elderly group: 12 months vs. 6 months, p < 0.001).DnMBC patients at different age have distinct metastasis patterns and prognostic features. The findings lend support to consideration of tailored management and surveillance strategies for different age patients.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.